Weight loss drug 'increases depression risk'

Advice to assess obese patients for depression before being given weight loss drug rimonabant has been reiterated following further evidence that the drug increases the risk of depression and anxiety.

It follows the findings of a meta-analysis of four trials carried out by Danish researchers that showed patients given rimonabant were 2.5 times more likely to stop treatment because of depression than those on placebo.

Patients were also three times more likely to quit treatment because of anxiety.

The four trials included a total of 4,105 patients who were randomly assigned 20mg rimonabant daily or placebo. Any patients suffering from depressed mood at baseline were excluded from the trial.

Patients given the drug had 4.7kg greater weight loss after the first year than those on placebo.

However, the rate of serious adverse events was 40 per cent higher in the treatment group.

In July this year, the EMEA said rimonabant should be contraindicated in those with major depression or those on antidepressants.

Dr David Haslam, clinical director of the National Obesity Forum, said GPs need to consider these contraindications before prescribing rimonabant.

A spokeswoman for manufacturer Sanofi-Aventis said it ‘has actively sought to ensure that treatment is prescribed to the right patient’.

rachel.liddle@haymarket.com


www.thelancet.com

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS England to redesign GP appraisal in light of COVID-19 pandemic

NHS England to redesign GP appraisal in light of COVID-19 pandemic

GP appraisals are being redesigned to have a greater focus on wellbeing and reduced...

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Primary care to lose millions in funding unless PCNs hit recruitment targets in pandemic

Hundreds of millions of pounds could be lost to primary care if primary care networks...

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

Practices told to prepare for 'major expansion' of flu vaccination as QOF pared back for 2020/21

GP practices have been told to 'gear up for a major expansion of the winter flu programme'...

NHS England unveils GP contract plans for second phase of COVID-19 response

NHS England unveils GP contract plans for second phase of COVID-19 response

GPs have been told to re-start health checks and other suspended services as NHS...

More than 80% of patients report 'good' overall experience of general practice

More than 80% of patients report 'good' overall experience of general practice

Public satisfaction with GP services remains high, with 82% of patients reporting...

GPs condemn 'deafening silence' from chancellor on COVID support funding

GPs condemn 'deafening silence' from chancellor on COVID support funding

GP leaders have condemned a 'deafening silence' on COVID-19 relief funding for general...